November 15, 2022

To,
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To,
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol- BIOCON

Dear Sir/Madam,

Subject: Investor Presentation – Q2 FY23.

With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: Investor Presentation
Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Biocon is a global biopharmaceutical enterprise that is led by a purpose to develop innovative solutions that provide affordable access to high quality, essential and life saving medicines for patients, payers and health systems across the world.
The Biocon Manifesto

As a committed stakeholder of the global health agenda under the UN Sustainable Development Goals (SDGs), Biocon has drawn up a manifesto to deliver on its commitment to universal healthcare.

**accessibility**
- Use our science, scale and expertise to enhance access to essential drugs for patients on the lowest rung of the economic ladder
- Uncover new medical insights aimed at expanding the scope of therapy to address unmet needs

**affordability**
- Focus on the kind of innovation that adds the condition of affordability to accessibility
- Bring competition for expensive innovator medicines through our generics and biosimilars

**availability**
- Build strategic global and regional partnerships to make high-quality biopharmaceuticals available to the maximum number of people
- Create a robust portfolio of ‘blockbuster’ drugs with the potential to benefit a billion patients

**assurance**
- Demonstrate the highest levels of ethics, compliance and governance
- Assure continuous supply of high-quality products conforming to international regulatory standards
The Biocon Value Creation Journey

1978-1999
An Enzymes Company

2000-2004
Transforming into a Biopharma Company
Successful IPO, Biocon listed in India (2004)

2005-2009
Building the Base Business and Expertise in Biologics
Enzymes Business Divested (2007)
Global Development of Biosimilars in Partnership with Mylan (2009)

2010-2015
Strategic Global Alliance with Mylan for Biosimilars Expanded (2013)
Generic Formulations Business Unit set up (2013)
IPO of Syngene (2015)

2016-2018
Commercialized Biosimilars for Diabetes & Cancer in Japan, U.S., EU
Global Partnership with Sandoz for Next-Gen Biosimilars (2018)

2019 & Beyond
Poised for Global Impact with Biosimilars
Investments in complex Generic Formulations

Unwavering focus through the years on research and innovation to create tangible differentiators for sustainable growth
Biocon Today: Strategically poised for a strong global play

Rs. 8,397 Cr | $1.1bn
Revenue*

~1,300
Patents*

~15,000
Total Employees*

50+
cGMP approvals from International regulatory agencies

120+
Countries where our products are available

Ranked 5
Among Top 10 Global Biotech Employers by Science magazine

* FY22
TransformAction: Transforming Sustainability at Biocon through Action

**PATIENT**
- 5.3M patients reached through biosimilars
- 13% revenue in gross R&D spend (Ex Syngene)

**PEOPLE**
- Top 5 among global pharma & biotech employer since 2012
- Recognized by UN Women for efforts to promote diversity
- 13% increase in women in workforce

**SOCIAL**
- Published Human Rights Policy
- Rs. 11 Crore in CSR Spend
- 120+ students graduated from Biocon Academy

**ENVIRONMENT**
- 58% electricity came from green power
- 100% waste water recycled & reused
- 118K tCO₂ GHG offset

**STAKEHOLDER**
- Board Committees, policies for global governance
- Published 1st Tax Policy & Transparency Report, Supplier Code of Conduct

---

FY22 Achievements

- Published 1st GRI aligned ESG & BRSR Report for FY22
- Featured for 1st time in 2021 in Emerging Markets Index with a score of 45; among top 15 in India
- Improved score of ‘B’ in 2021 in Climate Change & Water Security
- Secured ‘Bronze’ place, improved score of 52 in 2021

Click here to view our 1st ESG Report FY22
Business Segments
Growth Verticals: Aligned With Shifting Paradigms

From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally.

- **Ensuring access through quality, affordability, reliability**
- **Expanding access through innovative, inclusive healthcare solutions**
- **Pushing scientific boundaries to deliver impactful innovations**
- **Partnering to deliver innovative scientific solutions**
Generics: API – the building blocks

BUSINESS OVERVIEW

Among world’s largest manufacturers of statin & immunosuppressant APIs; leadership in Fermentation based APIs

Expertise in fermentation technology, large scale chromatography & synthetic chemistry

Balanced portfolio across cardiovascular, anti-diabetes, immunosuppressants, high potent API & few niche molecules for hospitals/institutions

Consistent quality compliance & regulatory approvals track record - U.S. FDA, EMA, TGA Australia, Health Canada, Cofepris Mexico

GLOBAL GENERIC API MARKET SIZE 2022E*

~$65b

40+ APIs

700+ API customers

75+ Countries served by API across US, Europe & large emerging markets

5 Facilities in India

GROWTH DRIVERS ACROSS STRATEGIC PRIORITIES

• Expanding beyond fermentation-based APIs (e.g. peptides, potent APIs)

• Investing in R&D - continuous manufacturing, bio transformation

• Augmenting capacities & capabilities:
  - Immunosuppressants (Vishakhapatnam)
  - Synthetic API (Hyderabad)
  - Additional fermentation capacities (Bengaluru)

• Expanding in select key markets

• Large customer acquisitions

• De-risking dependence for critical intermediates

*Source: Global Industry Analysts Inc.’s ‘Active Pharmaceutical Ingredients (API) - Global Market Trajectory & Analytics’ Report, March 2022
Generics: Forward integrating to Generic Formulations

**Business Overview**

- Leveraging in-house API expertise to forward integrate and move up the value chain
- Portfolio across therapeutic segments – CVS, Metabolics, Oncology, Immunology & Auto-immune indications
- Development pipeline includes oral solids (potent & non-potent), topical, parenteral & device dependent products
- Commercialised in the US; now expanding to select European & MoW markets; directly & through partners

**Growth Drivers Across Strategic Priorities**

- Expanding portfolio through
  - Vertical integration &
  - In-licensing strategy
- Adding capabilities
  - Injectable facility in Bengaluru
- Expanding beyond the US, either direct or through partners
  - Launched in EU, MoW
  - Direct Presence currently in select European markets & UAE
  - Partnerships in place in Southeast Asia, Mexico, Brazil and MENA

~$335b

Global Generics Drugs Market Size 2021*  
11 Commercial US Formulations  
5 Approved/ tentatively approved ANDAs

Generics: Q2 FY23 update

**KEY HIGHLIGHTS**

- Strong YoY growth both in API & generic formulations
- Sitagliptin and Vildagliptin API launches in EU
- Generic Formulations - Approvals in EU & MoW markets to aid geographical expansion
- Vizag immunosuppressant and Bangalore peptides facilities – Process validation batches are scheduled to commence in Q3 FY23

<table>
<thead>
<tr>
<th></th>
<th>Q2 FY23</th>
<th>Q2 FY22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>₹623Cr</td>
<td>₹530Cr</td>
</tr>
<tr>
<td><strong>Profit Before Tax (PBT)</strong></td>
<td>₹54Cr</td>
<td>₹50Cr</td>
</tr>
</tbody>
</table>

+18% 9% of revenue 9% of revenue +9%
Biosimilars: Overview

- Leadership in biologics R&D, manufacturing and commercialization built over two decades
- Driven by high scientific acumen with analytical and clinical capabilities in a complex regulatory setting
- Expertise in large scale biologics manufacturing across diverse technology platforms
- Product reach in over 75 countries including US, Europe, Canada, Japan and Australia
- Serve patients through commercial partners and direct sales force in India

8 Approved Products
2 Research & Development sites
3 Manufacturing sites (2 Bengaluru, 1 Malaysia)
25+ cGMP approvals (incl. FDA & EMA)

- Includes Adalimumab and Etanercept which have been in-licensed by Viatris and Biocon Biologics has economic interest.
- 2 Branded Formulations India (BFI) is the commercial platform in India
- 3 Only includes products where there has been company reported sales (Biosimilar sales only included for companies that report the numbers)
Biosimilar strategy resulted in several ‘firsts’

Achieved many firsts in the space despite the nascent biosimilars regulatory pathway, setting new benchmarks for the industry.

- **2004**: 1st company to commercialize human insulin using proprietary *P. pastoris* platform.
- **2017**: 1st company to receive approval for bTrastuzumab in the US.
- **2018**: 1st company to receive approval for bPegfilgrastim in the US.
- **2021**: 1st company to receive interchangeability for a biosimilar (glargine) in the US.
Growing participation in global biosimilars market

<table>
<thead>
<tr>
<th>PARTNER</th>
<th>BBL ROLE</th>
<th>BBL ECONOMICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mylan®</td>
<td>biosimilars co-developed and co-commercialized with R&amp;D and manufacturing led by BBL</td>
<td></td>
</tr>
<tr>
<td>Viatris</td>
<td>Acquisition* of Viatris’ biosimilar business to build a fully-integrated global biosimilar enterprise</td>
<td></td>
</tr>
<tr>
<td>SANDOZ (2018)</td>
<td>Set of next-gen biosimilars being co-developed</td>
<td></td>
</tr>
<tr>
<td>Biocon Biologics (ONGOING)</td>
<td>Independently developing several biosimilar assets</td>
<td></td>
</tr>
</tbody>
</table>

Collaboration with partners to build complementary capabilities, de-risking the journey in an uncharted territory

Note: * Transaction subject to regulatory approvals
Acquisition of Viatris’ biosimilars business to add financial depth and global commercial capabilities…

<table>
<thead>
<tr>
<th>1</th>
<th>Financial</th>
<th>BBL to realize full revenue and profits from all its collaboration programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Operational</td>
<td>Commercialization, Supply Chain and Regulatory capabilities in Developed Markets</td>
</tr>
<tr>
<td>3</td>
<td>New Growth Drivers</td>
<td>Launch of collaboration products in the US along with a new in-licensed biosimilar asset</td>
</tr>
</tbody>
</table>

**Revenue**

- **$1.1b**
- **$250m**

*Viatris Biosimilars CY23 estimate*

**EBITDA**

- **$1.1b**
- **$250m**

*Viatris Biosimilars CY23 estimate*

Viatris to provide commercial and transition services for an expected two-year period, at cost plus $44m p.a.

Note: Transaction subject to regulatory approvals | 1 BBL estimates of Viatris’ business

- bBevacizumab
- bAspart
- bAdalimumab
- bAflibercept
...transforming into a fully-integrated global biosimilars business

<table>
<thead>
<tr>
<th></th>
<th>Emerging Markets</th>
<th>Developed Markets</th>
<th>Global Markets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRODUCT DEVELOPMENT</strong></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>CLINICAL TRIALS</strong></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>REGULATORY</strong></td>
<td>✓</td>
<td>×</td>
<td>✓</td>
</tr>
<tr>
<td><strong>MANUFACTURING</strong></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>SUPPLY CHAIN</strong></td>
<td>✓</td>
<td>×</td>
<td>✓</td>
</tr>
<tr>
<td><strong>COMMERCIALIZATION</strong></td>
<td>✓</td>
<td>×</td>
<td>✓</td>
</tr>
</tbody>
</table>

POST ACQUISITION OF VIATRIS’ BIOSIMILARS BUSINESS

Note: Transaction subject to regulatory approvals
Funding the acquisition of Viatris’ biosimilar business

Acquisition of Viatris’ biosimilar business expected to close shortly

BBL has secured $1.2 bn in debt, balance amount to be funded through equity infusion.

EQUITY INFUSION IN BBL

SILS
Biocon Ltd
Reserves
Mezzanine Financing\*

\$150m
\$650m
\$230m
\$420m

On closing of the Viatris and Serum transactions, Biocon’s stake in Biocon Biologics will be 68%

Note: Transaction subject to regulatory approvals

*Biocon in the process of securing investments to retire the mezzanine finance, post deal closure.
Entering adjacencies in communicable disease: infectious disease antibodies and vaccines

Key Commercial Products (COVID-19)

- 50,000+ lives impacted

Recent Collaborations

- Continued portfolio expansion
Asset-light entry into vaccines through SILS alliance

BBL RIGHTS

1. Access to 100m doses of vaccines annually for ~15 years
2. Commercialization rights of the SILS portfolio for global markets
3. BBL to have committed revenue stream and related margins from H2 FY23

Alliance to commercialize SILS COVID portfolio and other next generation vaccines

Note: Transaction subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL);
Comprehensive portfolio of 20 biosimilars and vaccines...

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Molecule</th>
<th>US</th>
<th>Dev. Markets: ex-US</th>
<th>MoW⁴</th>
<th>Commentary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>Pegfilgrastim¹</td>
<td></td>
<td>Europe, CANZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trastuzumab¹</td>
<td></td>
<td>Europe, CANZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bevacizumab¹</td>
<td></td>
<td>Europe, AU, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Denosumab</td>
<td></td>
<td>Europe, CANZ, JP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pertuzumab¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunology</td>
<td>Adalimumab¹,²</td>
<td></td>
<td>Europe, CA, JP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Etanercept¹,²</td>
<td></td>
<td>Europe</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ustekinumab</td>
<td></td>
<td>UK, CANZ, JP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Glargine 100U¹,³</td>
<td></td>
<td>Europe, CANZ, JP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glargine 300U¹</td>
<td></td>
<td>Europe</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aspart¹</td>
<td></td>
<td>Europe, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rHI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone Health</td>
<td>Denosumab</td>
<td></td>
<td>Europe, CANZ, JP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undisclosed</td>
<td>7 Assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>Aflibercept⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Commentary**
- **bBevacizumab**: Approved in EU, Canada and Australia; US approval awaiting site inspection
- **bDenosumab**: Ph-1 and Ph-3 clinical trial ongoing
- **bAdalimumab**: US launch expected in mid-2023
- **bUstekinumab**: Ph-1 and Ph-3 clinical trial ongoing
- **rHI (US)**: BLA filing for various presentations
- **bAflibercept**: First-to-file in US

Access to SILS vaccine portfolio (Covishield and Covovax) and other next generation vaccines (e.g., mosquito-borne disease vaccines)⁶

---

¹ In partnership with Viatris; ² Partner Viatris has in-licensed product (Biocon benefits from economic interest); ³ Japan is outside of Viatris partnership; ⁴ MoW represents Most of the World markets. Chart represents the status of the country where the product is in most advanced stage. Every country has a different status; ⁵ Expected to be included in BBL portfolio post the completion of BBL’s acquisition of Viatris’ biosimilar business (Viatris has global rights to the program partnered with Momenta); ⁶ Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL)
…set up to deliver sustainable growth trajectory

**BIOCON BIOLOGICS GROWTH DRIVERS**

<table>
<thead>
<tr>
<th>Today</th>
<th>&lt; 2 years</th>
<th>2-4 years</th>
<th>&gt;4 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Pegfilgrastim</td>
<td>- Bevacizumab (US)</td>
<td>- Aflibercept&lt;sup&gt;2&lt;/sup&gt;</td>
<td>- Pertuzumab</td>
</tr>
<tr>
<td>- Trastuzumab</td>
<td>- Aspart (US)</td>
<td>- Ustekinumab</td>
<td>- Glargine 300 IU</td>
</tr>
<tr>
<td>- Bevacizumab (EU)</td>
<td>- Adalimumab (US)</td>
<td>- Denosumab</td>
<td>- Seven undisclosed programs</td>
</tr>
<tr>
<td>- Glargine 100 IU</td>
<td>- rH-Insulin (US)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Aspart (EU)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Adalimumab (EU)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Etanercept (EU)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Vaccines<sup>1</sup> (SILS collaboration)

---

1 Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL);
2 Expected to be included in BBL portfolio post the completion of BBL’s acquisition of Viatris’ biosimilar business (Viatris has global rights to the program partnered with Momenta)
Biosimilars: Q2 FY23 Update

**KEY HIGHLIGHTS**

- **Year-on-year revenue growth of 34%, reflecting the growth of insulin Glargine in US**
- **Core EBITDA margin benefitted from rupee depreciation and accrual of Performance Linked Incentives (PLI) benefits**
- **Progressing R&D pipeline with bDenosumab and bUstekinumab in clinic; R&D expense up 142% YoY**
- **Non-cash foreign currency translation loss of ₹35 Cr on GS OCD; ₹55 Cr gain in Q2 FY22 from mark-to-market movement on Adagio investment**
- **Fulphila’s US market shares surpassed 10% and Ogivri has started recovering following a temporary dip in Q1**
- **Submitted CAPA plan to US FDA for observations made in August site inspections**

**Q2 FY23**

- **Revenue**: ₹997 Cr
- **Core EBITDA**: ₹449 Cr (46% of revenue)
- **PBT before exceptions**: ₹78 Cr (8% of revenue)

**Q2 FY22**

- **Revenue**: ₹743 Cr
- **Core EBITDA**: ₹304 Cr (42% of revenue)
- **PBT before exceptions**: ₹174 Cr (23% of revenue)

*Core EBITDA defined as EBITDA excluding R&D, forex, licensing income and mark-to-market movement on investments*
Biocon Biologics offers differentiated value proposition through its state-of-the-art platform

1. Fully integrated global biosimilars company (lab to market)
2. Strong commercial presence in global markets
3. Comprehensive portfolio of insulins, mAbs and vaccines
4. Global scale biologics manufacturing capacity
5. Experienced management team with strong execution capabilities
6. Strong business financials enabling long-term growth
# Novel Molecules: Pushing scientific boundaries to deliver impactful innovations

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Asset</th>
<th>Current Progress</th>
</tr>
</thead>
</table>
| **Inflammation** | **Itolizumab**<sup>*</sup> | **Graft-Versus-Host Disease (GVHD)**
- **Pivotal Phase III Study initiated** in Mar ’22 for use in First-Line treatment of Acute GVHD; patient dosing initiated
- **European Commission granted an ‘Orphan Medical Product’ designation** for treatment of GVHD in Jul ’21 |
| **Immuno-oncology** | **BCA101**<sup>**</sup> | **Systemic Lupus Erythematosus/Lupus Nephritis (SLE/LN) indication**
- Encouraging interim data from the **Type B portion of the EQUALISE** study evaluating Itolizumab in patients with LN
- Study continues to enroll patients in the Type B portion, expects to share topline data in mid 2023 |
| | | **Ulcerative Colitis**
- Application for Phase 2 clinical trials in India for the treatment of Ulcerative Colitis using Itolizumab, approved by the DCGI |
| | | **BCA101**
- Formerly FmAb2
- First-in-class EGFR / TGFβ-trap bifunctional antibody
- **Phase I/II study initiated** at leading US and Canadian cancer centers in Jul ’20
- Under evaluation, both as a single agent & in combination with the checkpoint inhibitor, Pembrolizumab
  - Completed enrollment for dose finding part of Phase I trial & established highest dose with desired level of safety & tolerability.
  - In Feb ’22, initiated dose expansion cohorts in patients with head & neck squamous cell carcinoma (HNSCC), squamous cell carcinoma of the anal canal (SCAC) and cutaneous squamous cell carcinoma (cSCC)
  - Primary results expected in 2H22
- Securing external funding to support clinical development |

*partnered with Equillium Inc.

**part of Bicara Therapeutics Inc., a US based clinical-stage biotechnology company. In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.
Novels : Q2 FY23 Update

KEY HIGHLIGHTS

- **Itolizumab**: Equillium announced encouraging interim data from EQUALISE study in Lupus Nephritis

- Application to conduct Phase II Clinical Trial with Itolizumab for Ulcerative Colitis approved by DCGI

- **Bicara**: Continued progress in BCA 101

**Acute Graft-Versus-Host Disease**

*In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara Therapeutics Inc. to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.*
Research Services (Syngene) : Overview

- Offering integrated research, development & manufacturing services for small & large molecules, antibody-drug conjugates & oligonucleotides backed by best-in-class bioinformatic services
- World-class R&D and manufacturing infrastructure spread over 2 million square feet
- Audited successfully by US FDA, EMA, AAALAC and major life sciences partners
- Talented scientific & techno-commercial teams, led by experienced management, moving beyond cost arbitrage to innovation; 5200+ talented team of scientists, incl. ~500 PhDs
- ~400+ active clients across multiple sectors
- Strong track record of top-line growth with best-in-class EBITDA margins and Net Profit margin
- Listed in India on BSE and NSE in 2015

All figures are as on March 31, 2022, unless otherwise specified.
Research Services: Q2 FY23 Update

**KEY HIGHLIGHTS**

- **Positive performance across all divisions**
- **Sustained growth in research divisions - Discovery Services, including Synvent®, and the Dedicated Centres**
- **Growth in Development Services led by existing clients renewing contracts and setting up collaborations on additional projects**
- **Continued to invest in new infrastructure and capability-building**

<table>
<thead>
<tr>
<th>Q2 FY23</th>
<th>Q2 FY22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue from operations</strong></td>
<td>₹768 Cr</td>
</tr>
<tr>
<td><strong>Profit Before Tax (PBT)</strong></td>
<td>₹130 Cr</td>
</tr>
</tbody>
</table>

17% of revenue 19% of revenue

*Part of Syngene’s novel cancer drug discovery strategy for clients*
Financial Highlights
# Financial Highlights: Q2 FY23 (1/2)

<table>
<thead>
<tr>
<th></th>
<th>Q2 FY23</th>
<th>Q2 FY22</th>
<th>Adjusted for:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>₹2,384 Cr</td>
<td>₹1,945 Cr</td>
<td>Biosimilars +34%</td>
</tr>
<tr>
<td><strong>Core EBITDA</strong></td>
<td>+34% ₹816 Cr</td>
<td>+33% ₹609 Cr</td>
<td></td>
</tr>
<tr>
<td>% margin</td>
<td>35%</td>
<td>33%</td>
<td></td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>-3% ₹535 Cr</td>
<td>-3% ₹551 Cr</td>
<td><strong>Adjusted for:</strong> Dilution gain in Bicara of ₹33 Cr in Q2 FY23</td>
</tr>
<tr>
<td>% margin</td>
<td>22%</td>
<td>28%</td>
<td>MTM gain on investments ₹55 Cr Q2 FY22</td>
</tr>
<tr>
<td><strong>Profit Before Tax</strong></td>
<td>-11% ₹246 Cr</td>
<td>+11% ₹276 Cr</td>
<td>Gross R&amp;D spend at ₹252 Cr, up ₹86 Cr</td>
</tr>
<tr>
<td>(before exceptional charge)</td>
<td></td>
<td></td>
<td>R&amp;D spend in P&amp;L ₹242 Cr, up ₹96 Cr</td>
</tr>
<tr>
<td>% margin</td>
<td>10%</td>
<td>14%</td>
<td>Forex Loss of ₹82 Cr vs gain of ₹20 Cr in Q2 FY22</td>
</tr>
<tr>
<td><strong>Net Profit</strong></td>
<td>-10% ₹168 Cr</td>
<td>-10% ₹188 Cr</td>
<td></td>
</tr>
<tr>
<td>(before exceptional charge)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% margin</td>
<td>7%</td>
<td>10%</td>
<td></td>
</tr>
</tbody>
</table>

* Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark to market gain on investments
## Financial Highlights: Q2 FY23 (2/2)

<table>
<thead>
<tr>
<th>Description</th>
<th>Before Exceptional Charge</th>
<th>Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Profit</strong></td>
<td>₹168 Cr</td>
<td>₹188 Cr</td>
</tr>
<tr>
<td><strong>Exceptional Items</strong></td>
<td>₹122 Cr</td>
<td>₹50 Cr</td>
</tr>
<tr>
<td><strong>Net Profit (Reported)</strong></td>
<td>₹47 Cr</td>
<td>₹138 Cr</td>
</tr>
</tbody>
</table>

### Exceptional Items during Q2 FY23:
- **MAT credit balance charge of ₹107 Cr** on adoption of new tax regime of 25%. This move helps Biocon reduce tax outflow and P&L charge on a go-forward basis.
- **Professional fees, net of tax of ₹14 Cr** towards the Viatris deal
- **In Q2 FY22, exceptional items net of tax and minority were ₹50 Cr**
## Financial Highlights: FY22

<table>
<thead>
<tr>
<th>Category</th>
<th>FY 22</th>
<th>FY 21</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>₹8,397 Cr</td>
<td>₹7,398 Cr</td>
<td>+14%</td>
</tr>
<tr>
<td>Core EBITDA*</td>
<td>₹2,669 Cr</td>
<td>₹2,270 Cr</td>
<td>+18%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>₹2,183 Cr</td>
<td>₹1,907 Cr</td>
<td>+14%</td>
</tr>
<tr>
<td>Profit Before Tax</td>
<td>₹1,094 Cr</td>
<td>₹1,055 Cr</td>
<td>+4%</td>
</tr>
<tr>
<td>Net Profit</td>
<td>₹722 Cr</td>
<td>₹744 Cr</td>
<td>9%</td>
</tr>
</tbody>
</table>

*Core EBITDA defined as EBITDA before forex, R&D, mark-to-market loss on investments, licensing income and gain on dilution of stake in associates.*

- **Biosimilars +24% | Research Services +19% | Generics -1%**
- **Dilution Gain in Associates of ₹30 Cr vs ₹160 Cr in FY21**
- **Mark-to-market loss on investments of ₹28 Cr; Forex Gain of ₹58 Cr vs loss of ₹9 Cr in FY21**
- **Gross R&D spend at ₹711 Cr**
- **R&D spend in P&L ₹595 Cr**
- **Exceptional Loss at ₹111 Cr**
- **Net Profit after exceptional items at ₹648 Cr**